February 11, 2025

Super Bowl 2025, pharmaceutical advertising, Pfizer, Hims & Hers, ad likeability, viewer engagement, healthcare marketing, cancer awareness, weight loss drugs

Novartis Acquires Anthos Therapeutics for $925M, Regaining Control of Promising Anticoagulant Abelacimab

2 months ago talkbio0Tagged abelacimab, Acquisition, Anthos, Anticoagulants, Atrial Fibrillation, cardiovascular pipeline, Cerebrovascular accident, Factor XI antibody, Novartis

Novartis, Anthos Therapeutics, acquisition, abelacimab, anticoagulant, Factor XI inhibitor, atrial fibrillation, stroke prevention, cardiovascular pipeline

Eli Lilly Expands Oncology and Metabolic Disease Portfolio with Strategic Partnerships

2 months ago talkbio0Tagged AdvanCell, alpha therapies, cardiometabolic diseases, cellular targeting, Eli, Eli Lilly, MASH, OliX, Radiopharmaceuticals, strategic collaborations

Eli Lilly, AdvanCell, OliX Pharmaceuticals, targeted alpha therapies, radiopharmaceuticals, MASH, cardiometabolic diseases, strategic collaborations

Roivant’s Kinevant Discontinues Namilumab Development for Pulmonary Sarcoidosis After Phase 2 Failure

2 months ago talkbio0Tagged Drug Development, Failure (biologic function), Kinevant, namilumab, Phase 2 clinical trial, Roivant, Sarcoidosis, Pulmonary

Roivant Sciences, Kinevant, namilumab, pulmonary sarcoidosis, Phase 2 clinical trial, RESOLVE-Lung study, drug development failure

Boehringer Ingelheim’s Nerandomilast Achieves Second Phase III Success in Pulmonary Fibrosis Treatment

2 months ago talkbio0Tagged Boehringer, FIBRONEER-ILD, Force, Idiopathic Pulmonary Fibrosis, Ingelheim, nerandomilast, Phase 3 Clinical Trials, Progressive, Pulmonary Fibrosis, Respiratory physiology, Vital capacity

Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, lung function, forced vital capacity

Merck KGaA in Advanced Negotiations to Acquire SpringWorks Therapeutics

2 months ago talkbio0Tagged Acquisition, biopharmaceutical industry, cancer treatments, Does speak, Merck KGaA, Ogsiveo, SpringWorks

Merck KGaA, SpringWorks Therapeutics, acquisition talks, biopharmaceutical industry, rare diseases, cancer treatments, Ogsiveo

Eli Lilly Expands Pipeline with Strategic Deals in MASH and Cancer Therapies

2 months ago talkbio0Tagged AdvanCell, alpha therapies, Cancer Therapeutic Procedure, cardiometabolic diseases, cellular targeting, Eli, Eli Lilly, Interferes with, MASH, OliX, Radiopharmaceuticals, RNA

Eli Lilly, OliX Pharmaceuticals, AdvanCell, MASH, targeted alpha therapies, radiopharmaceuticals, RNA interference, cardiometabolic diseases, cancer treatment